Ajooni Biotech Ltd (AJOONI) — shareholding pattern, promoter holding, financials and share price
About Ajooni Biotech Ltd (AJOONI)
Ajooni Biotech Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as AJOONI and on the BSE under scrip code 535040. Its ISIN is INE820Y01021.
Incorporated in 2010, Ajooni Biotech Ltd is a vegetarian based animal health care solutions company. [1]
Ajooni Biotech Limited specializes in PURE VEG. animal healthcare solutions, prominently featured in the Indian cattle feed sector.
The company is expanding its production capacity, with a 70,000 MTPA increase planned in its cattle feed and supplement feed operations, reflecting its strategic focus on scaling up supply capabilities.
Listed peers in Pharmaceuticals: Source Natural Foods & Herbal Supplements Ltd, Vilin Bio Med Ltd, Onyx Biotec Ltd, Phaarmasia Ltd, Asston Pharmaceuticals Ltd, Vineet Laboratories Ltd.
Valuation & Returns
10 Jul 2026At ₹3.73 a share on 10 Jul 2026, Ajooni Biotech Ltd (AJOONI) was valued at a price-to-earnings ratio of 14.91x against an industry P/E of 36.41x and a price-to-book of 0.73x on a book value of ₹5.11 per share as of Mar 2025. Solomo computes return on equity of 4.89% and return on capital employed of 7.18% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 14.91x
- Industry P/E
- 36.41x
- P/B
- 0.73x
- EPS (TTM)
- ₹0.25
- Book value / share
- ₹5.11
- ROE
- 4.89%
- ROCE
- 7.18%
- ROA
- 4.53%
- Debt / equity
- 0.02x
- Dividend yield
- 0%
- EBITDA margin
- 4.76%
- 52-week range
- ₹3.4 – ₹6.15
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Ajooni Biotech Ltd (AJOONI) reported revenue of ₹182 crore, net profit of ₹4 crore and earnings per share of ₹0.25. That compares with revenue of ₹115 crore and net profit of ₹3 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹60.62 crore and net profit ₹0.95 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 74 | 74 | 80 | 115 | 182 |
| Net profit (₹ cr) | 1 | 1 | 2 | 3 | 4 |
| EPS (₹) | 0.05 | 0.06 | 0.12 | 0.2 | 0.25 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 27.12% | 23.43% | 15.71% | 43.17% |
| Profit growth | 48.42% | 57.60% | 47.59% | 56.02% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 26.89% of Ajooni Biotech Ltd (AJOONI) (unchanged from the previous quarter). Market capitalisation was ₹64 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2018.
Largest disclosed public shareholders in Jun 2026: ANANTHARAMAN JANAKI 1.9%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 26.89% | - | - | - | - |
| Mar 2026 | 26.89% | - | - | - | - |
| Dec 2025 | 26.89% | - | - | - | - |
| Sep 2025 | 26.89% | - | - | - | - |
| Jun 2025 | 26.89% | - | - | - | - |
| Mar 2025 | 26.89% | - | - | - | - |
| Dec 2024 | 26.89% | - | - | - | - |
| Sep 2024 | 26.89% | - | - | - | - |